Cancer immunotherapy has revolutionised cancer treatment, with immune checkpoint
blockade (ICB) therapy and adoptive cell therapy (ACT) increasingly becoming standard of …

Tertiary lymphoid structures (TLSs) are ectopic lymphoid organs that develop in non-
lymphoid tissues at sites of chronic inflammation including tumours. Key common …

Abstract CD4+ T cells and CD4+ chimeric antigen receptor (CAR) T cells display highly
variable antitumor activity in preclinical models and in patients; however, the mechanisms …

Current success of immunotherapy in cancer has drawn attention to the subsets of TH cells
in the tumor which are critical for activation of anti-tumor response either directly by …

There is abundant evidence that tumor-infiltrating CD8+ T cells contribute positively to
antitumor immunity; however, the role of tumor-infiltrating B cells (TIL-B) and plasma cells …

NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-
testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit …

It is now well established that the immune system can recognize developing cancers and
that therapeutic manipulation of immunity can induce tumor regression. The capacity to …

The immune system can identify and destroy nascent tumor cells in a process termed cancer
immunosurveillance, which functions as an important defense against cancer. Recently …

After a century of controversy, the notion that the immune system regulates cancer
development is experiencing a new resurgence. An overwhelming amount of data from …

Recent developments have set the stage for immunotherapy as a supplement to
conventional cancer treatment. Consequently, a significant effort is required to further …